60 Degrees Pharmaceuticals, Inc. Warrant closed at $0.03 on Sep 25, up 28.26%, 68.2% below its highest close since Jul 12. Volume of 5.1K shares was 1.31× its 20-day average (above normal).
Split-adjusted performance: -17.6% over one month, -59.3% over six months.
In the quarter ended Jun 30, 2026, revenue was $207.90K, down 32.5% from a year earlier, with a net margin of -1152.6%.
Short interest was 1.9K shares at the Sep 15 settlement (3.7 days to cover).
No recent articles focused on 60 Degrees Pharmaceuticals, Inc. Warrant. 1 articles mention it in passing.
Quick answers
What does 60 Degrees Pharmaceuticals, Inc. Warrant do?
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
What sector is SXTPW in?
Healthcare, in the Pharmaceuticals industry.
About 60 Degrees Pharmaceuticals, Inc. Warrant
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
